Shares of Nuvalent (NUVL) have soared nearly 20% in the past week owing to encouraging updates on its two investigational therapies. Both therapies target previously treated non-small cell lung cancer (NSCLC) patients but focus on different genetic mutations. These updates were announced earlier this weekend at the European Society for Medical Oncology (ESMO) Congress 2024 meeting held in Spain. NUVL Boasts Encouraging Pipeline Potential in NSCLC Space Management presented updated data from the early-stage ...